Core Viewpoint - Di'an Diagnostics has been awarded the "Brand Leading·Benchmark Enterprise" title at the 11th Excellent Brand Building Classic Case Evaluation, highlighting its success in brand construction within the healthcare industry [1] Group 1: Brand Development - The "Double Product Project" initiated by the Ministry of Industry and Information Technology in 2014 aims to strengthen brand development in China, promoting high-quality products and global competitiveness [1] - Di'an Diagnostics positions itself as a leader in "intelligent medical diagnostic solutions," utilizing "AI + data" to create a comprehensive health diagnostic industry chain [1] Group 2: Innovation and Services - The company actively explores service model innovations, leveraging big data and AI to support precise medical decision-making and public health management [2] - Di'an Diagnostics has launched over 10 data products on the Hangzhou Data Exchange platform, providing essential data support for precise diagnosis and scientific research [2] Group 3: Global Expansion - Di'an Biological, a subsidiary, has successfully promoted self-developed products in Europe, Southeast Asia, the Middle East, and Central Asia, obtaining over 70 registration certificates [2] - The company is gradually building a global medical diagnostic service network, enhancing the international influence of Chinese medical manufacturing [2] Group 4: Social Responsibility - Di'an Diagnostics has established a diversified public welfare support system, focusing on health initiatives, and has won the "Social Public Welfare Award" from the China Cancer Foundation for fourteen consecutive years [4] - The company is committed to environmental responsibility, contributing to national carbon peak and carbon neutrality goals through investments in green laboratory construction and data security governance [6]

来源：猎云网 近日，精准医疗企业吉因加完成3亿元D轮融资，本轮融资由绍兴市越城区科创引智基金、北京昌平产业发展投资基金等联合投资。 据了解，本轮融资将主要用于AI多组学技术研发、biomarker创新管线拓展及全球服务网络深化，进一步强化公司在精准诊断、新药研发等应用场景的全链 条服务能力，助力AI驱动的多组学技术从科研加速迈向临床转化。 吉因加科技（绍兴）股份有限公司成立于2015年4月，深耕精准医疗赛道，前瞻性推动基因大数据与临床实践的深度融合，在行业内率先建立多组学基线数 据库，构建起AI驱动的多组学平台，打造了"biomarker 发现&验证-产品化-商业化"全链条整合模式。在肿瘤MRD监测、NGS一体化精准诊断平台等领域取 得显著突破，业务覆盖肿瘤、感染、器官健康等多个疾病领域。 吉因加总裁杨玲表示，"我们始终聚焦临床需求，致力于将AI多组学创新技术转化为可及、可靠的临床解决方案。借助本轮融资的强大助力，我们将加大AI 多组学研发投入，加速MRD监测、肿瘤早筛等核心产品的转化与落地，同时积极拓展更多疾病诊断与治疗的应用新场景，持续夯实商业化全链条能力，让 AI多组学技术惠及更多患者与药企，为精准医疗 ...

11月18日至22日，国际知名乳腺肿瘤专家、希腊Rea医院Stefanos Zervoudis教授应邀到访山东大学齐鲁第二医院乳腺疾病诊疗中心和妇科开展为期五天的 学术交流、手术指导与科研合作，并正式受聘为齐鲁二院临床客座教授，齐鲁二院党委书记柳丽华为其颁发聘书，此次访问标志着齐鲁二院与国际顶尖团 队的合作迈上新台阶。 Zervoudis教授深耕乳腺与妇科肿瘤领域，学术足迹遍及希腊、法国等欧洲多国，其学术影响力辐射全欧。在手术交流环节他将国际前沿技术直接带至手 术台，现场指导完成两台高难度乳腺癌保乳手术，演示并讲解其首创的"半月形侧向肿瘤整形术"(Laterocrescent Half-Moon Oncoplasty)及"经乳头锥形切除 术"(Pyramidectomy)，同时引入团队研发的乳管镜刷检及乳管内灌洗系统，精准破解早期乳腺病变定位与微创处理难题。齐鲁二院医师全程跟学，就术式 要点与适应症等问题展开深度研讨。 学术讲座环节，Zervoudis教授围绕"乳腺癌外科治疗从根治到微创""肿瘤整形技术概述""乳头溢液诊治策略"三个主题作专题报告，结合希腊Rea医院临床 数据，分享乳管镜联合刷检在乳头溢液诊断 ...

Core Viewpoint - The article discusses a breakthrough in hydrogel technology developed by researchers at East China University of Science and Technology, which features a self-repairing gel that can revolutionize precision medicine through its unique ion-responsive properties [1][3][8]. Group 1: Scientific Discovery - The gel was initially thought to be a failed experiment when it disintegrated but surprisingly reformed itself the next day, leading to the discovery of its self-repairing capabilities [1][4]. - The research team identified the Hofmeister effect as the key scientific principle behind the gel's behavior, which involves specific ions affecting the arrangement of water molecules and thus the solubility of biological macromolecules [4][6]. - This discovery combines a century-old theory with modern dynamic self-assembly techniques, resulting in a supramolecular hydrogel capable of transitioning between gel and liquid states based on ionic conditions [6][8]. Group 2: Medical Applications - The ion-responsive gel addresses significant issues in traditional drug delivery systems, which often result in ineffective treatment due to either premature drug release or inability to deliver large molecules [8][11]. - The gel's mechanism allows for precise drug delivery by disintegrating in response to ion concentration changes, ensuring that medication is released directly at the target site [9][11]. - Its biocompatibility is enhanced compared to traditional covalently cross-linked hydrogels, allowing for minimally invasive treatments and easy clearance from the body post-application [11][12]. Group 3: Market Potential - The hydrogel technology has broader applications beyond drug delivery, including potential uses as ion sensors for monitoring specific ion concentrations in the body, which could lead to early disease detection [12][15]. - The Chinese hydrogel market is projected to reach approximately $4 billion by 2024, with expectations for further growth as smart materials become more prevalent [15][17]. - The research has garnered international attention, with publications in prestigious journals, indicating a strong interest in the technology within the academic and commercial sectors [15][17].

11月26日，"创新医疗：以色列与中国医疗科技合作"论坛在上海举办，本次活动汇聚来自上海的医疗界专业人士、投资者、企业领袖、研究人员，以及 来自以色列哈达萨医疗中心的顶尖专家团队，共同探讨人工智能、精准医疗等领域的开创性方法，开创合作新机遇。 现场，中以创新（泰兴）科技发展有限公司董事长、中以创新合作战略研究咨询专家委员介玉成向《国际金融报》记者表示，本次哈达萨医院来沪的行 程是在广泛而坚实的合作背景下展开的，此前，中以双方的医院就在科研、人员交流等方面建立过具体合作。以色列在医疗创新领域表现卓越，位居全球前 列，本次，以方也表现出主动对接中国市场的强烈意愿，该国在医疗等领域的尖端创新能力与中国巨大的市场需求和产业化能力形成了很好互补。 哈达萨医疗中心的专家团队带来了一系列前沿分享：哈达萨医疗中心副院长亚龙·伊兰（Yaron IIan ），重点分享了创新型AI系统。该系统通过分析个体 的生物变异性来预测疾病风险和优化治疗方案，从而显著改善患者预后；计算医学负责人谢伊·罗森伯格（Shai Rosenberg）探讨了"AI驱动的精准肿瘤学"， 展示了如何利用人工智能和机器学习模型为每一位肿瘤患者量身定制精准高效的 ...

齐鲁晚报.齐鲁壹点记者郭蕊通讯员陈丽艳王燕 近日，由济南市卫生健康委员会、济南医学会主办，济南市第四人民医院承办"济南医学会肿瘤学专业委员会2025年度学术会议、济南市肿瘤多学科诊疗 (MDT)医疗质量控制中心工作会议、济南医学会肿瘤放射治疗专业委员会2025年度学术会议、济南市肿瘤放射治疗专业医疗质量控制中心工作会议"在济 南顺利召开。本次会议汇聚了省内外近20家医疗机构的百余名肿瘤领域专家与同仁，聚焦诊疗前沿进展与临床实践中的关键问题，为济南地区乃至全省肿 瘤专业高质量发展提供了重要支持。 济南市卫生健康委员会医政医管处副处长王朝阳、济南医学会秘书长李怀斌、济南市第四人民医院党委书记孙郡等领导出席开幕式并致辞。会议由济南市 第四人民医院纪委书记李静主持。 济南市卫健委医政医管处副处长王朝阳讲话 济南医学会秘书长李怀斌讲话 济南市第四人民医院党委书记孙郡致辞 本次会议主题鲜明、内容充实，既是一次高水平学术交流盛会，也是一次凝聚共识、推动合作的动员会。与会同仁均感受益匪浅，会议受到广泛赞誉，为 济南地区肿瘤防治事业的高质量发展注入了新的活力与智慧，为"健康济南"建设写下了务实而崭新的一笔。 开幕式上，济南市第 ...

"每一次为患者手术，都是一份信任的托付。突破400例，意味着我们肩上的责任更重一分。"刘云川表示，"真正 的精准医疗，不在于追求最高的手术量，而在于为每一双眼睛找到最理想的手术方案。我们的核心差异在于，始 终坚持以专家的深度思考驾驭前沿技术，将科技的确定性与我们经验的灵活性相结合，为患者铺就一条安心、清 晰的视觉之路。" 日前，国内屈光手术权威专家、济南爱尔眼科（300015）医院刘云川院长主导的新一代蔡司VISUMAX800机器人 全飞秒手术(SMILE pro)成功突破400例。 400例手术，是四百次精准的个性化定制。在刘云川看来，顶尖设备是基石，而专家的"精"与"验"才是实现卓越疗 效的核心。每一台SMILE pro手术的背后，都是她基于深厚理论功底与数十年近视手术临床经验所做的精准判 断：面对不同的角膜条件与用眼需求，刘云川团队在术前进行精细化数据解读，确保手术方案与每位患者的眼部 条件及生活品质追求完美契合。凭借对设备性能的极致理解与炉火纯青的操作，她将"10秒内完成切削"的技术参 数，升华为"稳、准、柔"的患者手术体验，帮助患者获得长期、稳定的视觉健康。 ...

Core Viewpoint - Boda Pharmaceutical's stock has experienced a decline of 5.98% year-to-date, with significant drops over various time frames, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Boda Pharmaceutical achieved a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 669 million yuan, with 184 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 26, Boda Pharmaceutical's stock price was 50.52 yuan per share, with a market capitalization of 21.255 billion yuan. The stock saw a net inflow of 4.3816 million yuan from main funds [1]. - The company has seen a decrease in shareholder accounts, with a total of 29,500 shareholders as of September 30, down by 7.99%. The average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. Shareholder Composition - As of September 30, 2025, the top ten circulating shareholders include new entrants such as Xingquan Commercial Model Mixed Fund A and Xingquan Helun Mixed Fund A, while some funds like China Europe Medical Health Mixed Fund A have exited the top ten list [3].

Group 1 - The core viewpoint of the news is that Sely Medical has experienced significant stock price fluctuations, with a year-to-date increase of 191.14% but a recent decline of 33.31% over the past 60 days [1] - As of November 24, Sely Medical's stock price is 21.02 CNY per share, with a total market capitalization of 4.418 billion CNY [1] - The company has seen a net inflow of main funds amounting to 4.0757 million CNY, with significant trading activity reflected in the buying and selling of large orders [1] Group 2 - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, is primarily engaged in medical testing marketing and services, as well as the research, production, and sales of in vitro diagnostic products [2] - The company's revenue composition includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [2] - As of September 30, the company reported a revenue of 857 million CNY for the first nine months of 2025, a year-on-year decrease of 39.64%, and a net profit loss of 87.2441 million CNY, down 55.72% year-on-year [2] Group 3 - Since its A-share listing, Sely Medical has distributed a total of 27.0741 million CNY in dividends, with no dividends paid in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders include several new institutional investors, indicating a shift in shareholder composition [3]

Core Viewpoint - WuXi AppTec's stock price has shown significant growth this year, with a year-to-date increase of 75.56%, despite recent fluctuations in the short term [1][2]. Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [2]. - The net profit attributable to shareholders for the same period was 12.076 billion yuan, marking an impressive year-on-year increase of 84.84% [2]. Stock Market Activity - As of November 24, WuXi AppTec's stock price was 93.68 yuan per share, with a trading volume of 1.071 billion yuan and a turnover rate of 0.47% [1]. - The company experienced a net inflow of main funds amounting to 46.0942 million yuan, with significant buying and selling activities from large orders [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 274,100, reflecting a growth of 16.39% [2]. - The average number of circulating shares per shareholder remained stable at 9,024 shares [2]. Dividend Distribution - WuXi AppTec has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 249 million shares, a decrease of 52.6071 million shares from the previous period [3]. - Other notable institutional shareholders, such as Huaxia SSE 50 ETF and Huatai-PB CSI 300 ETF, also reported reductions in their holdings [3].